Benzinga | Apr 6, 2021 06:12AM EDT

Amarin Commences Commercial Initiatives For VAZKEPA In European Union Following Recent Regulatory Approval For Cardiovascular Risk Reduction Indication

Amarin Corporation plc (NASDAQ:AMRN) today provided updates regarding its plans for the commercial launch of VAZKEPA (icosapent ethyl) in Europe following the March 30, 2021 announcement of receipt of market authorization from the European Commission (EC). VAZKEPA is the first EC-approved product to be marketed and sold for cardiovascular risk reduction in high-risk, statin-treated adult patients who have elevated triglycerides (?150 mg/dL) and other risk characteristics as studied in REDUCE-IT(r).